Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07332481 · ClinicalTrials.gov registry record · Phase 3
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
A Phase 3 study, sponsored by EMD Serono Research & Development Institute.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 202
- Enrollment target
NCT07332481 is a Phase 3 study that is actively recruiting participants, run by EMD Serono Research & Development Institute. The registered enrollment target is 202 participants.
The verdict
NCT07332481, a Phase 3 study, is actively recruiting participants, sponsored by EMD Serono Research & Development Institute.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 202 participants
- Enrollment target
Study Summary
The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration: Up to 35 weeks. Treatment Duration: 24 weeks. Visit Frequency: every 4 weeks, with the exception of the Week 2 televisit. Study Intervention Name: Enpatoran, Placebo. Intervention Form: Film-coated tablet.
Interventions
- DRUG Placebo
- DRUG Enpatoran
- DRUG Standard of care (SoC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2026-03-10 |
| Est. Completion | 2029-05-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07332481
The ClinicalTrials.gov registry entry for NCT07332481 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07332481 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07332481 about?
NCT07332481 is a clinical study titled "A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease". The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration: Up to 35 weeks. Treatment Dur...
What is the current status of trial NCT07332481?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 202 participants. The study started on 2026-03-10. Estimated completion is 2029-05-24.
What interventions are being tested in trial NCT07332481?
The interventions under investigation include: Placebo (DRUG), Enpatoran (DRUG), Standard of care (SoC) (DRUG).
Who is sponsoring clinical trial NCT07332481?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.